This CLE webinar will closely examine the recent proclamation issued by the Trump administration imposing 100% tariffs on imported patented pharmaceuticals and related ingredients under Section 232 of the Trade Expansion Act of 1962 (Section 232). The panel will discuss the complex tiered rate structure and address the impact these changes will have on the pharmaceutical industry, including cost increases and potential supply chain issues. The panel will also offer best practices for compliance.
The Trump administration recently issued a proclamation imposing sweeping tariffs on patented pharmaceuticals and related ingredients under Section 232, citing threats to national security and the economy as the reason.
Beginning as early as July 31, 2026 for certain large pharmaceutical companies and becoming widely effective on Sept. 29, 2026 for all covered entities, a baseline tariff of 100% will be imposed on imports of patented pharmaceuticals, biologics, and associated ingredients impacting pharmaceutical manufacturers, importers, and supply chain participants.
The proclamation establishes a complex, multi-tiered rate structure and allows for certain company, country, and product-specific tariff reductions and exemptions—all with the purpose of pushing companies toward domestic manufacturing and pricing concessions.
Counsel with clients in the pharmaceutical and life sciences industries should have a clear understanding of the new tariff structure and how it will impact their clients, including cost increases, supply chain disruptions, and changes in business practices.
Listen as our expert panel closely examines the recent proclamation and the new tariff structure. The panel will address the impact these changes will have on the pharmaceutical industry and discuss next steps that counsel and clients should be taking now.
